3B Blackbio Diagnostics Ltd Stock Price Today (NSE: 3BBLACKBIO)
3B Blackbio Diagnostics Ltd
Fundamental Score
3B Blackbio Diagnostics Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
3B Blackbio Diagnostics Ltd share price today is ₹1272.00, up +6.47% on NSE/BSE as of 17 July 2026. 3B Blackbio Diagnostics Ltd (3BBLACKBIO) is a Small-cap company in the Healthcare Service Provider sector with a market capitalisation of ₹1.08K (Cr). The 52-week high for 3BBLACKBIO share price is ₹1750.00 and the 52-week low is ₹1083.50. At a P/E ratio of 18.42x, 3BBLACKBIO is currently trading below its industry average P/E of 42.23x. The company has a Return on Equity (ROE) of 19.77% and a debt-to-equity ratio of 0.01.
3B Blackbio Diagnostics Ltd Share Price Chart — NSE/BSE Historical Performance
3B Blackbio Diagnostics Ltd share price chart: -0.85% return over the past month. 52-week high ₹1750.00, 52-week low ₹1083.50.
3B Blackbio Diagnostics Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1194.65 | ₹1284.80 | ₹1183.35 | ₹1272.00 | 11.14K (Cr) | |
| ₹1280.00 | ₹1280.00 | ₹1165.00 | ₹1194.70 | 2.96K (Cr) | |
| ₹1135.05 | ₹1216.00 | ₹1133.00 | ₹1210.20 | 3.07K (Cr) | |
| ₹1176.00 | ₹1199.80 | ₹1134.55 | ₹1153.30 | 2.12K (Cr) | |
| ₹1195.95 | ₹1200.00 | ₹1165.75 | ₹1171.10 | 1.34K (Cr) | |
| ₹1168.50 | ₹1224.45 | ₹1130.30 | ₹1174.40 | 2.74K (Cr) | |
| ₹1240.00 | ₹1240.00 | ₹1166.00 | ₹1170.80 | 1.67K (Cr) | |
| ₹1178.80 | ₹1220.00 | ₹1164.75 | ₹1205.20 | 1.67K (Cr) | |
| ₹1220.00 | ₹1220.00 | ₹1170.00 | ₹1172.50 | 2.54K (Cr) | |
| ₹1203.90 | ₹1210.00 | ₹1185.60 | ₹1207.75 | 148.00 (Cr) |
3B Blackbio Diagnostics Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1186.80 | ₹1284.80 | ₹1130.30 | ₹1272.00 | +7.18% | |
| ₹1179.10 | ₹1309.45 | ₹1083.50 | ₹1168.60 | -0.89% | |
| ₹1200.65 | ₹1413.00 | ₹1177.00 | ₹1244.05 | +3.61% | |
| ₹1151.00 | ₹1409.00 | ₹1110.00 | ₹1206.60 | +4.83% | |
| ₹1302.00 | ₹1404.70 | ₹1120.00 | ₹1126.00 | -13.52% | |
| ₹1643.95 | ₹1720.00 | ₹1323.05 | ₹1351.50 | -17.79% | |
| ₹1400.05 | ₹1750.00 | ₹1370.00 | ₹1667.45 | +19.10% | |
| ₹1319.90 | ₹1464.00 | ₹1151.00 | ₹1404.95 | +6.44% | |
| ₹1374.00 | ₹1439.00 | ₹1175.30 | ₹1286.30 | -6.38% | |
| ₹1374.80 | ₹1453.00 | ₹1311.00 | ₹1377.85 | +0.22% | |
| ₹1431.00 | ₹1500.00 | ₹1310.00 | ₹1374.80 | -3.93% | |
| ₹1584.00 | ₹1679.85 | ₹1403.00 | ₹1434.40 | -9.44% |
AI Research Briefing
Powered by Gemini · 2026-04-17
Decent growth story but rich valuation and micro-cap risk limit upside.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. Trading window closed on April 1st, 2026, ahead of FY26 results. Investors await the board meeting announcement for FY26 results.
CORE STORY (THE REAL GAME)
3B Blackbio is a play on the growth of molecular diagnostics in India, riding the wave of increased healthcare spending and a shift towards preventative care. The Coris BioConcept acquisition signals a move towards global expansion and product diversification.
- Strong revenue growth in 9M FY26
- Expansion into global markets with Coris BioConcept acquisition
- Guidance for 10-15% revenue and EBITDA growth
- Strong FY26 results
- Successful integration of Coris BioConcept
- Entry into the US market
- Micro-cap liquidity risk
- Rich valuation
- Integration risk with Coris BioConcept
FII decreased by 0.06% and DII increased by 0.06% [cite: brief].
Healthcare spending in India is increasing, providing a tailwind for diagnostic companies.
Yes - Free Cash Flow 5Y: ₹218.07 Cr [cite: brief]
Expect continued growth in revenue and profitability, driven by expansion in India and globally. Key risk is the successful integration of Coris BioConcept.
Primary Thesis Risk
Failure to integrate Coris BioConcept acquisition will destroy the thesis.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
3B Blackbio Diagnostics Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
3B Blackbio Diagnostics Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of 3BBLACKBIO across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (19.77%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (25.48%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (45.29%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 18.42 vs Industry: 42.23)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Revenue Growth (57.47%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.01)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (321.71x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹149.20 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Limited Growth History (-8.95% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-14.76% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-12.44% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Limited Institutional Interest (FII+DII: 4.65%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
3B Blackbio Diagnostics Ltd vs Healthcare Service Provider Peers
Peer Comparison - Healthcare Service Provider
Compare 3B Blackbio Diagnostics Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
3B Blackbio Diagnostics Ltd3B Blackbio Dia...Selected✓ 3BBLACKBIO • 532067 | 60.3/100 | ₹1272.00₹1272 | ₹1079.13₹1079.13 | 18.42Average 18.4 Average | 19.77%Good 19.77% Good | 25.48%Excellent 25.48% Excellent | 0.01Excellent 0.0 Excellent | -12.44%Poor -12.44% Poor | -8.95%Poor -8.95% Poor | 0.31% |
Dr Lal PathLabs LtdDr Lal PathLabs... LALPATHLAB • 539524 | 57.7/100 | ₹1723.30₹1723 | ₹28908.91₹28908.91 | 55.39Average 55.4 Average | 22.30%Excellent 22.30% Excellent | 28.00%Excellent 28.00% Excellent | 0.08Excellent 0.1 Excellent | 12.33%Good 12.33% Good | 11.81%Good 11.81% Good | 0.81% |
Vijaya Diagnostic Centre LtdVijaya Diagnost... VIJAYA • 543350 | 67.8/100 | ₹1261.40₹1261 | ₹14307.85₹14307.85 | 82.71Average 82.7 Average | 19.74%Good 19.74% Good | 21.29%Excellent 21.29% Excellent | 0.44Excellent 0.4 Excellent | 15.47%Excellent 15.47% Excellent | 16.66%Excellent 16.66% Excellent | 0.14% |
Metropolis Healthcare LtdMetropolis Heal... METROPOLIS • 542650 | 57.9/100 | ₹571.65₹572 | ₹11858.49₹11858.49 | 60.38Average 60.4 Average | 13.81%Average 13.81% Average | 17.77%Good 17.77% Good | 0.15Excellent 0.1 Excellent | 1.46%Average 1.46% Average | 10.52%Good 10.52% Good | 0.35% |
Krsnaa Diagnostics LtdKrsnaa Diagnost... KRSNAA • 543328 | 31.9/100 | ₹549.05₹549 | ₹1777.47₹1777.47 | 17.31Average 17.3 Average | 10.89%Average 10.89% Average | 12.70%Average 12.70% Average | 0.54Good 0.5 Good | -11.13%Poor -11.13% Poor | 11.75%Good 11.75% Good | 0.50% |
Sastasundar Ventures LtdSastasundar Ven... SASTASUNDR • 533259 | 39/100 | ₹301.45₹301 | ₹1035.54₹1035.54 | 539.34Average 539.3 Average | 0.29%Poor 0.29% Poor | -0.05%Poor -0.05% Poor | 0.04Excellent 0.0 Excellent | 16.91%Excellent 16.91% Excellent | 19.09%Excellent 19.09% Excellent | 0.00% |
49.4/100 | ₹245.70₹246 | ₹600.78₹600.78 | 20.55Average 20.6 Average | 19.92%Good 19.92% Good | 23.27%Excellent 23.27% Excellent | 0.31Excellent 0.3 Excellent | — — | — — | 0.00% | |
Aspira Pathlab & Diagnostics LimitedAspira Pathlab ... ASPIRA • 540788 | 11.9/100 | ₹86.00₹86 | ₹88.52₹88.52 | 1770.34Average 1770.3 Average | 0.51%Poor 0.51% Poor | 2.84%Poor 2.84% Poor | 0.27Excellent 0.3 Excellent | -48.50%Poor -48.50% Poor | 10.43%Good 10.43% Good | 0.00% |
Choksi Imaging LtdChoksi Imaging ... CHOKSI • 526546 | 36.3/100 | ₹174.55₹175 | ₹81.49₹81.49 | 54.33Average 54.3 Average | 6.10%Poor 6.10% Poor | 9.64%Poor 9.64% Poor | 1.20Average 1.2 Average | 20.80%Excellent 20.80% Excellent | 12.36%Good 12.36% Good | 0.00% |
Medinova Diagnostic Services IncMedinova Diagno... MEDINOV • 526301 | 49/100 | ₹43.45₹43 | ₹43.37₹43.37 | 20.17Average 20.2 Average | — — | 108.87%Excellent 108.87% Excellent | — — | 56.49%Excellent 56.49% Excellent | 5.66%Good 5.66% Good | 0.00% |
Bandaram Pharma Packtech LtdBandaram Pharma... BANDARAM • 524602 | 19.3/100 | ₹23.18₹23 | ₹41.66₹41.66 | 92.57Average 92.6 Average | 2.28%Poor 2.28% Poor | 4.42%Poor 4.42% Poor | 0.89Good 0.9 Good | — — | — — | 0.43% |
Top Healthcare Service Provider Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Dr Lal PathLabs Ltd share price28908.91 Cr
- Vijaya Diagnostic Centre Ltd share price14307.85 Cr
- Metropolis Healthcare Ltd share price11858.49 Cr
- Krsnaa Diagnostics Ltd share price1777.47 Cr
- Sastasundar Ventures Ltd share price1035.54 Cr
3B Blackbio Diagnostics Ltd PE Ratio History
Historical price-to-earnings ratio for 3BBLACKBIO — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹37.46 | ₹1978.65 | 52.8x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
3B Blackbio Diagnostics Ltd Dividend History
Annual cash dividends paid by 3BBLACKBIO — dividend yield 0.31%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹2.57 Cr |
| FY 2024 | ₹2.19 Cr |
| FY 2023 | ₹4.44 Cr |
| FY 2022 | ₹15.46 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
3B Blackbio Diagnostics Ltd Quarterly Performance
Latest quarterly metrics for 3BBLACKBIO — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
57.47%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
13.81%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-8.95%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-12.44%
Compounded annual net profit growth over 5 years
3B Blackbio Diagnostics Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for 3BBLACKBIO — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
3B Blackbio Diagnostics Ltd Financial Statements
Annual income statement, balance sheet and cash flow for 3B Blackbio Diagnostics Ltd (3BBLACKBIO) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for 3B Blackbio Diagnostics Ltd
About 3BBLACKBIO (3B Blackbio Diagnostics Ltd)
3B Blackbio Diagnostics Ltd is a pioneering force in the healthcare sector, dedicated to revolutionizing disease detection and management through innovative molecular diagnostic so...lutions. The company is deeply invested in designing, developing, and manufacturing cutting-edge diagnostic tools that span a wide range of critical medical fields. From the intricate complexities of infectious diseases and oncology to the nuanced landscape of human genetics and the ever-growing threat of antimicrobial resistance, 3B Blackbio is committed to providing healthcare professionals with the power to make informed decisions, ultimately improving patient outcomes. At the heart of 3B Blackbio's mission lies a comprehensive portfolio of molecular diagnostic kits, each meticulously crafted to deliver accurate and reliable results. These kits utilize advanced technologies such as qPCR-based assays, rapid lateral flow tests, and Next Generation Sequencing (NGS), ensuring a versatile approach to diagnostics. Marketed under the TRUPCR, TRUNGS, and TRURAPID brands, these solutions empower diagnostic laboratories to perform comprehensive testing on patient samples, enabling faster and more precise diagnoses. The company's commitment to innovation and quality ensures that healthcare providers have access to the most advanced tools available. 3B Blackbio Diagnostics Ltd stands as a vital partner in the fight against disease, striving to empower clinicians with the knowledge they need to provide the best possible care. By continuously pushing the boundaries of molecular diagnostics, 3B Blackbio is not only transforming the way diseases are detected and managed, but also contributing to a healthier future for all. Their dedication to innovation, accuracy, and accessibility makes them a key player in the evolving landscape of healthcare.
Company Details
Key Leadership
Corporate Events
Latest News
3BBLACKBIO Share Price: Frequently Asked Questions
What is the current share price of 3B Blackbio Diagnostics Ltd?
3B Blackbio Diagnostics Ltd (3BBLACKBIO) trades at ₹1272.00 on NSE and BSE. Market cap ₹1.08K (Cr). Educational data only.
What is the P/E ratio of 3B Blackbio Diagnostics Ltd?
3B Blackbio Diagnostics Ltd has a P/E of 18.42x vs industry average 42.23x.
What is the Bull Run score for 3B Blackbio Diagnostics Ltd?
3B Blackbio Diagnostics Ltd has a Bull Run score of 60.3/100 based on 25+ financial parameters.
Does 3B Blackbio Diagnostics Ltd pay dividends?
3B Blackbio Diagnostics Ltd has a dividend yield of 0.31%. Past dividends don't guarantee future payments.
What is the ROE of 3B Blackbio Diagnostics Ltd?
3B Blackbio Diagnostics Ltd has ROE of 19.77%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of 3B Blackbio Diagnostics Ltd?
3B Blackbio Diagnostics Ltd has debt-to-equity of 0.01.
Is 3B Blackbio Diagnostics Ltd a good investment?
Bull Run gives 3B Blackbio Diagnostics Ltd a score of 60.3/100. This is not investment advice — consult a SEBI-registered advisor.